Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

NanoSight Announce New Appointment

Published: Tuesday, June 26, 2012
Last Updated: Tuesday, June 26, 2012
Bookmark and Share
Leading UK scientist, Dr Andrew Shuttleworth, joins NanoSight board as Director of Diagnostic Sciences.

NanoSight announced the appointment of renowned UK scientist and former government advisor, Dr Andrew Shuttleworth, as Director of Diagnostic Sciences.

NanoSight welcomes Dr Andrew Shuttleworth to the board of the company in the capacity of Director of Diagnostic Sciences. Dr Shuttleworth's appointment further strengthens the scientific team. His experience will greatly add to NanoSight's position as the UK's fastest growing Biotechnology company.

Andrew Shuttleworth brings a wealth of scientific knowledge to the rapidly expanding NanoSight organization. Having been awarded degrees in in applied biological sciences and virology, he spent twenty years at Porton Down research establishments involved in both fundamental research in microbiology and immunology, and the application of that research to medical and defense issues; particularly the rapid identification of select biological agents. This led to a leading role in the development of the UK's first practical biological agent detection system, fielded during the Gulf War in 1991, and acted as the scientific liaison on chemical and biological issues with UK and US Forces throughout the Gulf region. Andrew returned to Porton Down where he directed a team of analytical chemists, microbiologists and operational analysts providing chemical and biological risk and threat assessments. He also provided real-time operational advice and support to the Ministry of Defence, the Home Office and other government departments. In 2001, Andrew took up an appointment with the UK Foreign & Commonwealth Office to provide scientific advice and expertise on a diverse range of topics of national interest.

CEO Jeremy Warren says "Our growing involvement in characterization of exosomes and microvesicles has been driven by users. Increasingly we are recognizing major potential in exosome diagnostics, so the fit with Andrew is remarkable. He has followed development of NanoSight's technology since we began and been an advisor to some of our shareholders plus he has a depth of diagnostics experience. This appointment is as obvious as it is attractive for all parties."

Andrew Shuttleworth comments: "The emerging field of exosomes and nanovesicles now looks set to give rise to a fundamental shift in the way in which disease is detected, diagnosed and monitored. Currently, it is a growing research field, which NanoSight is exploiting fully through the provision of increasingly capable research instrumentation. Eventually, multiple biomarkers will be identified for each relevant disease state and this will drive the development of new analytical capabilities. Whilst it is too early to suggest that NanoSight technology will supplant existing capabilities (e.g. ELISA, qPCR), it would be prudent to recognize that NanoSight has the potential to do so – particularly where multiple-parameter tests and quantitative results might be desirable. NanoSight also has the potential to assist in the development of other novel assay systems that might be needed to fully exploit the potential benefits of exosomes and nanovesicles."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Method Development to Estimate the Purity of Vesicle Preparations
Nanoparticle tracking analysis is used to estimate the purity of vesicle preparations at the Cardiff University School of Medicine.
Thursday, February 28, 2013
Landmark Publication Reports Potential of Exosomes as Biomarkers for Early Disease Detection
NanoSight reports the new publication in one of the most cited peer reviewed journals in nanoscience and nanotechnology, NanoMedicine.
Thursday, July 07, 2011
NanoSight announces interactive webinar on January 27th on Exosome Characterization by Nanoparticle Tracking Analysis
NanoSight, world-leading manufacturers of unique nanoparticle characterization technology, will host an interactive webinar on the subject of exosome characterization by Nanoparticle Tracking Analysis.
Thursday, January 20, 2011
Scientific News
Rare Immunodeficiency Yields Unexpected Insights
Scientists uncover previously unknown gene mutation revealing the role of a key molecule involved in immune cell development.
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
IU Research Reveals Link between Molecular Mechanisms in Prostate Cancer and Ewing's sarcoma
Researchers at IU have suggested that the molecular mechanism that triggers the rare disease Ewing's sarcoma could act as a potential new direction for the treatment of more than half of patients with prostate cancer.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
RNA-Binding Proteins Role in ALS Revealed
Researchers describe how damage to RNA-binding protein contributes to ALS, isolating a possible therapeutic target.
Advances in Alzheimer’s Research
Researchers show how a diseased vertebrate brain can naturally react to Alzheimer’s pathology by forming more neurons.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Alzheimer’s-Linked Protein May Play Role in Schizophrenia
Researchers suggests a protein linked to cognitive decline in Alzheimer's also plays a role in genetic predisposition to schizophrenia.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos